FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	$D \subset$	20549	
vasilligion,	D.C.	20349	

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Troendle August J.				2. Issuer Name and Ticker or Trading Symbol  Medpace Holdings, Inc. [ MEDP ]								(Chec	k all app Direc	tor	<u> </u>	<b>(</b> 10% (	Owner		
(Last) (First) (Middle) C/O MEDPACE HOLDINGS, INC. 5375 MEDPACE WAY			3. Date of Earliest Transaction (Month/Day/Year) 07/21/2020							X	Officer (give title below)  Other (specify below)  President & CEO								
(Street) CINCINNATI OH 45227			4. If a	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ind Line) X	fividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				son			
(City)	(S	tate) (2	Zip)																
		Table	: I - I	Non-Deriva	tive	Secu	rities	Acc	quir	ed, D	isposed	of, or	Bene	ficiall	y Own	ed			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		T C	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an				Beneficially Owned Followin				7. Nature of Indirect Beneficial Ownership		
							С	Code V		Amount	(A) oi (D)	(A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)	
Common	Stock				$\top$										61	6,643		D	
Common Stock 07/21/20		07/21/202	)		:	S <sup>(1)</sup>		28,090(1)	D	\$10	6.78 <sup>(2)</sup>	7,673,077		I		By Medpace Investors, LLC <sup>(3)</sup>			
Common Stock 07/		07/22/202	20		S		S <sup>(1)</sup>		35,878(1)	D	\$10	9.99(4)	7,637,199			I	By Medpace Investors, LLC <sup>(3)</sup>		
		Ta	ble	II - Derivati (e.g., pu							sposed of				Owne	d			
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Instr. 3)  3. Transaction Date Execution Date, if any (Month/Day/Year)  (Month/Day/Year)			ecution Date, ny	4. Transaction Code (Instr. 8) Securiti Acquire (A) or Dispose of (D) (Instr. 3, and 5)		ative rities ired osed	Exp	oiration	ercisable and Date y/Year)	Ame Sec Und Der Sec	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Dat Exe	e ercisab	Expiration Date	n Title	Amor or Numl of Share	ber					

## **Explanation of Responses:**

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.
- 2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$105.32 to \$107.74. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- 3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 4. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$106.89 to \$111.26. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

/s/ Stephen P. Ewald, Attorney-in-Fact for August J. 07/23/2020 Troendle

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.